Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels

Area of Science:

• Biomedical research
• Molecular biology
• Endocrinology

Background:

• Glucocorticoids, like dexamethasone (Dex), are widely used but can cause bone fragility due to osteopenia.
• This bone loss results from impaired osteoblast function and increased bone resorption.
• The precise molecular mechanisms by which Dex affects bone metabolism are not fully understood.

Purpose of the Study:

• To investigate how dexamethasone (Dex) influences osteoclastogenesis.
• To analyze the effect of Dex on the expression of osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in osteoblastic cells.
• To elucidate the role of c-Jun signaling in mediating Dex-induced changes in OPG expression.

Main Methods:

• Coculture system to study osteoclastogenesis.
• Analysis of OPG and RANKL gene and protein expression using Western blotting and transcript analysis.
• Investigation of c-Jun signaling pathways, including Jun N-terminal kinase (JNK) and mitogen-activated protein (MAP) kinases.
• Use of MAP kinase inhibitors to assess pathway involvement.

Main Results:

• Dexamethasone (Dex) significantly reduced OPG transcripts and protein secretion in ST2 osteoblastic cells.
• Dex decreased the phosphorylation of c-Jun and the p46 isoform of JNK, indicating inhibition of the JNK/c-Jun pathway.
• A JNK inhibitor mimicked Dex's inhibitory effect on OPG promoter activity, confirming JNK's role.
• Dex showed a nominal increase in RANKL gene expression and partially suppressed beta-catenin signaling.

Conclusions:

• Dexamethasone (Dex) mediates bone resorption primarily by inhibiting OPG production.
• This inhibition occurs through transrepression of the OPG gene via the AP-1 site, dependent on reduced JNK activity and subsequent decrease in phospho-c-Jun.
• The findings highlight the JNK/c-Jun pathway as a key mediator of glucocorticoid-induced bone loss.